GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (OTCPK:SRTOY) » Definitions » Cyclically Adjusted FCF per Share

SRTOY (Sartorius Stedim Biotech) Cyclically Adjusted FCF per Share : $0.32 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Sartorius Stedim Biotech Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sartorius Stedim Biotech's adjusted free cash flow per share for the three months ended in Dec. 2024 was $0.221. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.32 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Sartorius Stedim Biotech's average Cyclically Adjusted FCF Growth Rate was 14.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2025-04-13), Sartorius Stedim Biotech's current stock price is $17.62. Sartorius Stedim Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2024 was $0.32. Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF of today is 55.06.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Sartorius Stedim Biotech was 161.90. The lowest was 53.68. And the median was 95.00.


Sartorius Stedim Biotech Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Sartorius Stedim Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Cyclically Adjusted FCF per Share Chart

Sartorius Stedim Biotech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.25 0.30 0.32

Sartorius Stedim Biotech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.27 0.28 0.32 0.32

Competitive Comparison of Sartorius Stedim Biotech's Cyclically Adjusted FCF per Share

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF falls into.


;
;

Sartorius Stedim Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sartorius Stedim Biotech's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.221/127.0412*127.0412
=0.221

Current CPI (Dec. 2024) = 127.0412.

Sartorius Stedim Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201212 0.000 97.957 0.000
201306 0.000 98.516 0.000
201312 0.000 99.356 0.000
201406 0.000 99.543 0.000
201412 0.000 99.543 0.000
201506 0.000 100.417 0.000
201512 0.000 99.717 0.000
201606 0.000 100.717 0.000
201612 0.000 101.217 0.000
201706 0.000 102.117 0.000
201709 0.000 102.717 0.000
201712 0.000 102.617 0.000
201803 0.014 102.917 0.017
201806 0.005 104.017 0.006
201809 0.025 104.718 0.030
201812 0.021 104.217 0.026
201903 0.059 104.217 0.072
201906 0.034 105.718 0.041
201909 0.058 106.018 0.070
201912 0.058 105.818 0.070
202003 0.107 105.718 0.129
202006 0.068 106.618 0.081
202009 0.134 105.818 0.161
202012 0.010 105.518 0.012
202103 0.183 107.518 0.216
202106 0.147 108.486 0.172
202109 0.122 109.435 0.142
202112 0.033 110.384 0.038
202203 0.113 113.968 0.126
202206 -0.028 115.760 -0.031
202209 0.042 118.818 0.045
202212 0.084 119.345 0.089
202303 0.058 122.402 0.060
202306 0.000 123.140 0.000
202309 -0.012 124.195 -0.012
202312 0.277 123.773 0.284
202403 -0.060 125.038 -0.061
202406 0.154 125.882 0.155
202409 0.213 126.198 0.214
202412 0.221 127.041 0.221

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Sartorius Stedim Biotech  (OTCPK:SRTOY) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Sartorius Stedim Biotech's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=17.62/0.32
=55.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Sartorius Stedim Biotech was 161.90. The lowest was 53.68. And the median was 95.00.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sartorius Stedim Biotech Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius Stedim Biotech Business Description

Address
Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.

Sartorius Stedim Biotech Headlines